4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 32 Issue 6
Oct.  2018
Turn off MathJax
Article Contents
Abstract
Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
Citation: Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
shu

Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer

  • 1.

    Department of Public Health and Preventive Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu 222000, China

  • 2.

    Department of Pathology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, China

  • 3.

    Department of Clinical Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu 222000, China

  • 4.

    Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China

  • 5.

    Department of Epidemiology, Department of Social Medicine and Health Education, The Innovation Center for Social Risk Governance in Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China

Funds: 

This work was supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (grant number 17KJD330002)

the Science and Technology Development Fund of Nanjing Medical University (grant number 2017NJMUZD141) and the Science and Technology Development Fund of Kangda College of Nanjing Medical University (grant number KD2016KYJJZD007, KD2016KYJJZD008). The funding agencies had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.

More Information
  • Received Date: June 19, 2017
  • Revised Date: May 20, 2018
    Graphical Abstract
    • Abstract
  • Identifying sensitive and specific biomarkers for early detection of cancer is immensely imperative for early diagnosis and treatment and better clinical outcome of cancer patients. This study aimed to construct a specific DNA methylation pattern of cancer suppressor genes and explore the feasibility of applying cell-free DNA based methylation as a biomarker for early diagnosis of esophageal squamous cell carcinoma (ESCC). We recruited early stage ESCC patients from Yangzhong County, China. The Illumina Infinium 450K Methylation BeadChip was used to onstruct a genome-wide DNA methylation profile. Then, differentiated genes were selected for the validation study using the Sequenom MassARRAY platform. The frequency of methylation was compared between cancer tissues, matched cell-free DNAs and normal controls. The specific methylation profiles were constructed, and the sensitivity and specificity were calculated. Seven CG sites in three genes CASZ1, CDH13 and ING2 were significantly hypermethylated in ESCC as compared with normal controls. A significant correlation was found between the methylation of DNA extracted from cancer tissues and matched plasma cell-free DNA, either for individual CG site or for cumulative methylation analysis. The sensitivity and specificity reached 100% at an appropriate cut-point using these specific methylation biomarkers. This study revealed that aberrant DNA methylation is a promising biomarker for molecular diagnosis of esophageal cancer. Hypermethylation of CASZ1, CDH13 and ING2 detected in plasma cell-free DNA can be applied as a potential noninvasive biomarker for diagnosis of esophageal cancer.
    • FullText(HTML)
    • References (0)
    • Related Articles

  • Cited by

    Periodical cited type(14)

    1. Najib Ullah SNM, Afzal O, Altamimi ASA, et al. Bedaquiline-Loaded Solid Lipid Nanoparticles Drug Delivery in the Management of Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals (Basel), 2023, 16(9): 1309. DOI:10.3390/ph16091309
    2. Amrutkar CS, Patil SB. Nanocarriers for ocular drug delivery: Recent advances and future opportunities. Indian J Ophthalmol, 2023, 71(6): 2355-2366. DOI:10.4103/ijo.IJO_1893_22
    3. Gugleva V, Andonova V. Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms. Pharmaceuticals (Basel), 2023, 16(3): 474. DOI:10.3390/ph16030474
    4. Albarqi HA, Garg A, Ahmad MZ, et al. Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma. Pharmaceutics, 2023, 15(2): 681. DOI:10.3390/pharmaceutics15020681
    5. Shawky S, Makled S, Awaad A, et al. Quercetin Loaded Cationic Solid Lipid Nanoparticles in a Mucoadhesive In Situ Gel-A Novel Intravesical Therapy Tackling Bladder Cancer. Pharmaceutics, 2022, 14(11): 2527. DOI:10.3390/pharmaceutics14112527
    6. Wang J, Wang H, Xu H, et al. Solid lipid nanoparticles as an effective sodium aescinate delivery system: formulation and anti-inflammatory activity. RSC Adv, 2022, 12(11): 6583-6591. DOI:10.1039/d1ra07638h
    7. Bonilla L, Espina M, Severino P, et al. Lipid Nanoparticles for the Posterior Eye Segment. Pharmaceutics, 2021, 14(1): 90. DOI:10.3390/pharmaceutics14010090
    8. Yu Z, Ding W, Aleem MT, et al. Toxoplasma gondii Proteasome Subunit Alpha Type 1 with Chitosan: A Promising Alternative to Traditional Adjuvant. Pharmaceutics, 2021, 13(5): 752. DOI:10.3390/pharmaceutics13050752
    9. González-Fernández FM, Bianchera A, Gasco P, et al. Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation. Pharmaceutics, 2021, 13(4): 447. DOI:10.3390/pharmaceutics13040447
    10. Gorantla S, Rapalli VK, Waghule T, et al. Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Adv, 2020, 10(46): 27835-27855. DOI:10.1039/d0ra04971a
    11. Chrissian C, Lin CP, Camacho E, et al. Unconventional Constituents and Shared Molecular Architecture of the Melanized Cell Wall of C. neoformans and Spore Wall of S. cerevisiae. J Fungi (Basel), 2020, 6(4): 329. DOI:10.3390/jof6040329
    12. Mahmood S, Kiong KC, Tham CS, et al. PEGylated Lipid Polymeric Nanoparticle-Encapsulated Acyclovir for In Vitro Controlled Release and Ex Vivo Gut Sac Permeation. AAPS PharmSciTech, 2020, 21(7): 285. DOI:10.1208/s12249-020-01810-0
    13. Zamboulis A, Nanaki S, Michailidou G, et al. Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments. Polymers (Basel), 2020, 12(7): 1519. DOI:10.3390/polym12071519
    14. Jumelle C, Gholizadeh S, Annabi N, et al. Advances and limitations of drug delivery systems formulated as eye drops. J Control Release, 2020, 321: 1-22. DOI:10.1016/j.jconrel.2020.01.057

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article has an altmetric score of 1
    Article has an altmetric score of 1
    Article views (3748) PDF downloads (482) Cited by(14)
    Related

    ©2023 by the Editorial Department of the Journals of Nanjing Medical University. All rights reserved.   苏ICP备05071376号-5

    Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail: info@rhhz.net  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return